Congress Just Passed a Research Funding Bill That Rejects Nearly Every White House Cut. Here Is What It Means for Grant Seekers.

For the better part of a year, the research community has operated under a cloud of uncertainty so thick that some principal investigators stopped writing proposals altogether. The administration proposed cutting NIH funding by 40 percent. It attempted to cap indirect cost reimbursement at 15 percent — a move that would have defunded entire research universities. It restricted the release of FY2026 funds to what the Office of Management and Budget deemed "essential," leaving thousands of new grant awards in limbo.

Then the House voted 397 to 28 to pass a spending package that rejects virtually every one of those proposals.

The FY2026 Labor, Health and Human Services, Education, and Related Agencies appropriations bill — bundled with Commerce, Justice, Science and Energy and Water Development — preserves the funding infrastructure that American research depends on. It is not a victory lap. The Senate still has to act, and the political dynamics there are complicated. But for researchers, university administrators, and small businesses that compete for federal R&D funding, this bill is the most important signal of the year about where the money will actually land.

What the House Bill Actually Funds

National Institutes of Health: $48.7 billion. This represents a $415 million increase over FY2025 enacted levels and a bipartisan repudiation of the administration's proposed 40 percent reduction. The increase is modest in real terms — it roughly tracks inflation — but the political statement is unmistakable: Congress is not willing to dismantle the world's largest biomedical research enterprise.

The bill also maintains funding for the Advanced Research Projects Agency for Health (ARPA-H) at $1.5 billion, preserving the Biden-era initiative that the administration had proposed eliminating. ARPA-H funds high-risk, high-reward health research projects that traditional NIH study sections often decline — precisely the kind of work that generates breakthrough therapies.

National Science Foundation: $8.75 billion. NSF's allocation preserves its position as the primary federal funder of fundamental research across every scientific discipline. The agency has announced plans to issue 10,000 new research awards in FY2026, an increase driven partly by efficiency initiatives that reduce the administrative burden per award and partly by a deliberate push to broaden the geographic distribution of funding beyond the traditional coastal research corridors.

Department of Energy Office of Science: $8.4 billion. The nation's largest funder of physical sciences research retains its budget, supporting ongoing programs in physics, chemistry, materials science, computing, and the Genesis Mission AI initiative that DOE announced earlier this month.

Institute of Education Sciences: $790 million. This is perhaps the most striking line item in the bill — the administration had requested just $261 million, and Congress tripled it. IES funds the rigorous evaluation research that determines which education interventions actually work, and its preservation signals that Congress values evidence-based policymaking even when the executive branch does not.

The Indirect Cost Rate Battle Is Not Over

Buried in the appropriations language is a provision that may matter more to research institutions than any individual funding number: the bill explicitly blocks the administration's proposed 15 percent cap on NIH indirect cost reimbursement rates. It goes further, including additional language aimed at preventing changes to negotiated indirect cost rates across all Department of Health and Human Services research agencies.

This is a direct response to the DOE's decision to impose a standardized 15 percent rate on its own grants — a policy that took effect earlier this year and has already begun reshaping how universities budget DOE-funded research. The House bill draws a line: what DOE did unilaterally, HHS will not be permitted to do.

The stakes are enormous. Negotiated indirect cost rates at major research universities typically range from 50 to 65 percent, reflecting the actual costs of maintaining research infrastructure — lab space, safety compliance, administrative support, library systems, and IT. A 15 percent cap would force institutions to either subsidize federal research from other revenue sources (primarily tuition) or decline to host federally funded research at all. Neither outcome serves the national interest.

But the protection is only as strong as the final enacted bill. If the Senate modifies the language, or if the provision is traded away in conference negotiations, the indirect cost rate remains vulnerable. University government relations offices should be treating this provision as their single highest lobbying priority between now and final passage.

The Senate Complication

The House passed its package with overwhelming bipartisan support — 397 to 28 is about as close to unanimous as modern Congress gets on spending legislation. The Senate's path is more treacherous.

Democratic senators have signaled they may block consideration of the package unless Department of Homeland Security funding is separated from the broader bill. The dispute centers on ICE enforcement operations, not research funding, but the procedural leverage affects everything in the bundled appropriation. A January 30 funding deadline — already passed — means the government is operating under a continuing resolution that freezes spending at FY2025 levels.

For researchers, the continuing resolution is not neutral. It prevents new program launches, blocks funding increases that the House bill provides, and maintains the OMB spending restrictions that have already reduced NIH's competitive grant awards by 74 percent compared to historical averages for the same period. Every month that the CR continues is a month in which the pipeline of new research awards stalls further.

The Senate Appropriations Committee has advanced its own version of the LHHS bill with similar NIH funding levels — $48.7 billion — suggesting bipartisan agreement on the topline number even if the legislative vehicle remains contested. The most likely outcome is eventual passage at or near the House levels, but the timing is uncertain. Researchers should plan for a scenario in which full-year appropriations do not arrive until mid-2026.

What This Means for Grant Seekers Right Now

The appropriations trajectory creates a specific set of strategic imperatives for anyone competing for federal research funding.

NIH applicants should submit now, not later. When full-year appropriations eventually pass, NIH will face enormous pressure to obligate funds quickly. The agency has a backlog of meritorious applications that scored well but could not be funded under CR restrictions. New submissions that arrive during the current cycle will be reviewed and ready for funding when the money flows. Waiting for certainty is the wrong strategy — by the time certainty arrives, the review cycle will be months behind.

NSF's 10,000-award target is real. The combination of stable funding and administrative streamlining means NSF is actively looking to increase its award count. Programs like the new independent research organization initiative and expanded CAREER awards represent genuine new funding opportunities, not repackaged existing programs. Applicants who were discouraged by past success rates should reconsider.

DOE researchers face a split landscape. The Office of Science budget is preserved, but the 15 percent indirect cost cap on DOE grants is already in effect. Institutions with high negotiated rates are either absorbing the difference or declining to submit DOE proposals — which means less competition for institutions with lower overhead structures. Community colleges, primarily undergraduate institutions, and national lab affiliates may find DOE opportunities more accessible than in previous cycles.

Small businesses should watch SBIR/STTR timelines closely. The reauthorization that passed Congress earlier this month establishes new award categories and application limits, and agencies are expected to publish their first solicitations under the new rules in the coming weeks. The appropriations bill funds the agencies; the reauthorization structures the programs. Both pieces are now in place.

The Larger Stakes

The FY2026 appropriations battle is fundamentally a debate about whether the United States will continue to invest in the research infrastructure that has driven its economic and technological leadership for 80 years. The House vote suggests that even in a divided government with sharp ideological disagreements about the size and scope of federal spending, the bipartisan consensus behind publicly funded research remains intact.

That consensus has limits. The increases are modest. The indirect cost protections are legislative, not permanent policy. And the gap between what agencies are authorized to spend and what OMB allows them to release creates real-world funding delays that no appropriations bill can fully resolve.

But for researchers and institutions that spent 2025 wondering whether their fields had a future in the federal funding ecosystem, the House vote provides the clearest answer yet: Congress is not walking away from science. The money is there. The question is whether your proposal will be ready when it arrives. Tools like Granted can help you track agency-level funding announcements and identify the specific solicitations that align with your research as they publish.